FOLH1 and Familial prostate cancer: There is an increasing use of RNT for patients with extensive bone metastases from castration-resistant prostate cancer, for example with 223Ra or radiolabelled prostate-specific membrane antigen (PSMA) ligands (possibly even subsequently) [39, 40].